Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose 5-aminolevulinic acid safety study during PDD-TURBT in elderly patients with renal impairment
jRCTs031250795Recruiting
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 5-aminolevulinic acid in bladder cancer. Primary endpoint: Incidence rate of composite events. Started Sep 2026; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
bladder cancer
Beyond the preview
Go deeper on jRCTs031250795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250795.